New combo shows promise for tough ovarian cancer
NCT ID NCT04938583
First seen Apr 08, 2026 · Last updated May 08, 2026 · Updated 6 times
Summary
This study tests a new drug called oregovomab added to standard chemotherapy and bevacizumab for people with a certain type of recurrent ovarian cancer. The goal is to see if the combination is safe and helps shrink tumors. About 54 adults with BRCA-normal ovarian cancer that came back after initial treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Hospital
Seoul, Seoul, 05505, South Korea
-
CHA Bundang Medical Center
Seongnam-si, 13496, South Korea
-
Korea Anam Hospital
Seoul, Seoul, 02841, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Seoul St. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.